Breast Cancer

Articles

Novel eganelisib shows survival-extending potential in patients with triple-negative breast and bladder cancers.  

Eganelisib Combination Therapies Demonstrate Promising Survival Benefit in Advanced Urothelial Carcinoma and TNBC

Based on results of the KEYNOTE-522 trial, the FDA approved pembrolizumab, the first immunotherapy for this indication, plus chemotherapy as neoadjuvant treatment for patients with early-stage triple-negative breast cancer.

FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit. 

Leronlimab Plus Carboplatin Appears to Yield Survival Benefit in Metastatic Triple-Negative Breast Cancer 

Pembrolizumab plus chemotherapy as adjuvant/neoadjuvant therapy demonstrated positive even-free survival outcomes in the KEYNOTE-522 study for patients with triple-negative breast cancer. 

Event-Free Survival Improvement Noted in KEYNOTE-522 Study for Patients With Triple-Negative Breast Cancer

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients. 

Neoadjuvant Durvalumab Plus Chemotherapy Effective in Early-Stage TNBC

Black women with triple-negative breast cancer may have worse survival outcomes compared with White women, even after adjusting for external factors.

Outcome Data for Black Women With Early TNBC Suggest Research Needed to Combat Disparities

Pembrolizumab plus chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy in patients with early triple-negative breast cancer was superior in terms of event-free survival versus matched placebo. 

KEYNOTE-522 Meets EFS End Point in High-Risk, Early TNBC

The TROP2-directed antibody-drug conjugate datopotamab deruxtecan induced responses and an acceptable safety profile in a cohort of patients with triple-negative breast cancer treated on a phase 1 trial. 

Datopotamab Deruxtecan Shows Promise in Heavily Pretreated Triple-Negative Breast Cancer 

The FDA’s Oncologic Drugs Advisory Committee voted 7 to 2 in favor of atezolizumab plus nab-paclitaxel maintaining its accelerated approval to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.

Triple-Negative Breast Cancer | Topics